Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

Safety Study Using Photodynamic Therapy Light Therapy for Patients With Chest Wall Progression of Breast Cancer and Satellite Metastases of Melanoma
A Phase I Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) for Patients Failing Radiation Therapy
Status: Archived
Tufts Clinical Pharmacology Study Unit
mi
from
Boston, MA
Safety Study Using Photodynamic Therapy Light Therapy for Patients With Chest Wall Progression of Breast Cancer and Satellite Metastases of Melanoma
A Phase I Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) for Patients Failing Radiation Therapy
Status: Archived
Updated: 1/1/1970
Tufts Clinical Pharmacology Study Unit
mi
from
Boston, MA
Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma
A Phase II Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen in Metastatic Melanoma
Status: Archived
Aurora Sinai Medical Center / St. Lukes Medical Center
mi
from
Milwaukee, WI
Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma
A Phase II Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen in Metastatic Melanoma
Status: Archived
Updated: 1/1/1970
Aurora Sinai Medical Center / St. Lukes Medical Center
mi
from
Milwaukee, WI
Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors
A Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LDE225 in Patients With Advanced Solid Tumors
Status: Archived
University of Pittsburg Medical Center
mi
from
Pittsburgh, PA
Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors
A Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LDE225 in Patients With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
University of Pittsburg Medical Center
mi
from
Pittsburgh, PA
Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors
A Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LDE225 in Patients With Advanced Solid Tumors
Status: Archived
Cancer Therapy and Research Center
mi
from
San Antonio, TX
Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors
A Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LDE225 in Patients With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Cancer Therapy and Research Center
mi
from
San Antonio, TX
A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors
A Phase I, Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the BRAF Inhibitor GSK2118436 in Subjects With Solid Tumors
Status: Archived
GSK Investigational Site
mi
from
Anaheim, CA
A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors
A Phase I, Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the BRAF Inhibitor GSK2118436 in Subjects With Solid Tumors
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Anaheim, CA
A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors
A Phase I, Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the BRAF Inhibitor GSK2118436 in Subjects With Solid Tumors
Status: Archived
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors
A Phase I, Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the BRAF Inhibitor GSK2118436 in Subjects With Solid Tumors
Status: Archived
Updated: 1/1/1970
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors
A Phase I, Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the BRAF Inhibitor GSK2118436 in Subjects With Solid Tumors
Status: Archived
GSK Investigational Site
mi
from
Knoxville, TN
A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors
A Phase I, Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the BRAF Inhibitor GSK2118436 in Subjects With Solid Tumors
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Knoxville, TN
A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors
A Phase I, Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the BRAF Inhibitor GSK2118436 in Subjects With Solid Tumors
Status: Archived
GSK Investigational Site
mi
from
Austin, TX
A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors
A Phase I, Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the BRAF Inhibitor GSK2118436 in Subjects With Solid Tumors
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Austin, TX
Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly
PHASE IIIB, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF AN 84-MG OCTREOTIDE SUBCUTANEOUS HYDROGEL IMPLANT IN SUBJECTS WITH ACROMEGALY
Status: Archived
Clinical Trial Facility
mi
from
Denver, CO
Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly
PHASE IIIB, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF AN 84-MG OCTREOTIDE SUBCUTANEOUS HYDROGEL IMPLANT IN SUBJECTS WITH ACROMEGALY
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Denver, CO
Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly
PHASE IIIB, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF AN 84-MG OCTREOTIDE SUBCUTANEOUS HYDROGEL IMPLANT IN SUBJECTS WITH ACROMEGALY
Status: Archived
Clinical Trial Facility
mi
from
Centralia, IL
Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly
PHASE IIIB, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF AN 84-MG OCTREOTIDE SUBCUTANEOUS HYDROGEL IMPLANT IN SUBJECTS WITH ACROMEGALY
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Centralia, IL
Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly
PHASE IIIB, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF AN 84-MG OCTREOTIDE SUBCUTANEOUS HYDROGEL IMPLANT IN SUBJECTS WITH ACROMEGALY
Status: Archived
Clinical Trial Facility
mi
from
Chevy Chase, MD
Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly
PHASE IIIB, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF AN 84-MG OCTREOTIDE SUBCUTANEOUS HYDROGEL IMPLANT IN SUBJECTS WITH ACROMEGALY
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Chevy Chase, MD
Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly
PHASE IIIB, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF AN 84-MG OCTREOTIDE SUBCUTANEOUS HYDROGEL IMPLANT IN SUBJECTS WITH ACROMEGALY
Status: Archived
Clinical Trial Facility
mi
from
Lima, OH
Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly
PHASE IIIB, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF AN 84-MG OCTREOTIDE SUBCUTANEOUS HYDROGEL IMPLANT IN SUBJECTS WITH ACROMEGALY
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Lima, OH
Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly
PHASE IIIB, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF AN 84-MG OCTREOTIDE SUBCUTANEOUS HYDROGEL IMPLANT IN SUBJECTS WITH ACROMEGALY
Status: Archived
Clinical Trial Facility
mi
from
Medford, OR
Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly
PHASE IIIB, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF AN 84-MG OCTREOTIDE SUBCUTANEOUS HYDROGEL IMPLANT IN SUBJECTS WITH ACROMEGALY
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Medford, OR
Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly
PHASE IIIB, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF AN 84-MG OCTREOTIDE SUBCUTANEOUS HYDROGEL IMPLANT IN SUBJECTS WITH ACROMEGALY
Status: Archived
Clinical Trial Facility
mi
from
Mountlake Terrace, WA
Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly
PHASE IIIB, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF AN 84-MG OCTREOTIDE SUBCUTANEOUS HYDROGEL IMPLANT IN SUBJECTS WITH ACROMEGALY
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Mountlake Terrace, WA
A Study of GSK2118436 in BRAF Mutatant Metastatic Melanoma to the Brain
BRF113929: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain
Status: Archived
GSK Investigational Site
mi
from
Anaheim, CA
A Study of GSK2118436 in BRAF Mutatant Metastatic Melanoma to the Brain
BRF113929: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Anaheim, CA
A Study of GSK2118436 in BRAF Mutatant Metastatic Melanoma to the Brain
BRF113929: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain
Status: Archived
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
A Study of GSK2118436 in BRAF Mutatant Metastatic Melanoma to the Brain
BRF113929: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain
Status: Archived
Updated: 1/1/1970
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
A Study of GSK2118436 in BRAF Mutatant Metastatic Melanoma to the Brain
BRF113929: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain
Status: Archived
GSK Investigational Site
mi
from
Knoxville, TN
A Study of GSK2118436 in BRAF Mutatant Metastatic Melanoma to the Brain
BRF113929: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Knoxville, TN
A Study of GSK2118436 in BRAF Mutatant Metastatic Melanoma to the Brain
BRF113929: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain
Status: Archived
GSK Investigational Site
mi
from
Kennewick, WA
A Study of GSK2118436 in BRAF Mutatant Metastatic Melanoma to the Brain
BRF113929: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Kennewick, WA
AZD2171 and Whole Brain Radiation Therapy (WBRT) in Patients With Brain Metastases
A Phase I Study of AZD2171 and WBRT in Patients With Brain Metastases
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
AZD2171 and Whole Brain Radiation Therapy (WBRT) in Patients With Brain Metastases
A Phase I Study of AZD2171 and WBRT in Patients With Brain Metastases
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
AZD2171 and Whole Brain Radiation Therapy (WBRT) in Patients With Brain Metastases
A Phase I Study of AZD2171 and WBRT in Patients With Brain Metastases
Status: Archived
Dana-Farber Cancer Institute
mi
from
Boston, MA
AZD2171 and Whole Brain Radiation Therapy (WBRT) in Patients With Brain Metastases
A Phase I Study of AZD2171 and WBRT in Patients With Brain Metastases
Status: Archived
Updated: 1/1/1970
Dana-Farber Cancer Institute
mi
from
Boston, MA
Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage IV Melanoma
Phase I/II Study To Evaluate The Safety Of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cell Clones Following CD25 Lymphodepletion For Patients With Metastatic Melanoma
Status: Archived
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage IV Melanoma
Phase I/II Study To Evaluate The Safety Of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cell Clones Following CD25 Lymphodepletion For Patients With Metastatic Melanoma
Status: Archived
Updated: 1/1/1970
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma
Phase I Biochemotherapy With Cisplatin, Temozolomide, With Increasing Doses of Abraxane, Combined With Interleukin-2 and Interferon in Patients With Metastatic Melanoma
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma
Phase I Biochemotherapy With Cisplatin, Temozolomide, With Increasing Doses of Abraxane, Combined With Interleukin-2 and Interferon in Patients With Metastatic Melanoma
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma
Psilocybin-assisted Psychotherapy in the Management of Anxiety Associated With Stage IV Melanoma.
Status: Archived
Mount Sinai Comprehensive Cancer Center at Mount Sinai Medical Center
mi
from
Miami Beach, FL
Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma
Psilocybin-assisted Psychotherapy in the Management of Anxiety Associated With Stage IV Melanoma.
Status: Archived
Updated: 1/1/1970
Mount Sinai Comprehensive Cancer Center at Mount Sinai Medical Center
mi
from
Miami Beach, FL
Interstitial Fluid Pressure (IFP) Pilot Study in Melanoma Patients
A Pilot Study Assessing the Feasibility and Safety of Measuring Interstitial Fluid Pressure (IFP) in Patients With Advanced Malignant Melanoma Before Starting Systemic Treatment
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Interstitial Fluid Pressure (IFP) Pilot Study in Melanoma Patients
A Pilot Study Assessing the Feasibility and Safety of Measuring Interstitial Fluid Pressure (IFP) in Patients With Advanced Malignant Melanoma Before Starting Systemic Treatment
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Comparison of Standard of Care or Treatment on Protocol
Randomized Study of Patients (Patient Choice) Who Are Not Eligible for Variations of Standard of Care Protocols When Treated Either on Best Standard of Care Pathways or Per a Protocol Arm That They Failed to Enroll to
Status: Archived
University of New Mexico
mi
from
Albuquerque, NM
Comparison of Standard of Care or Treatment on Protocol
Randomized Study of Patients (Patient Choice) Who Are Not Eligible for Variations of Standard of Care Protocols When Treated Either on Best Standard of Care Pathways or Per a Protocol Arm That They Failed to Enroll to
Status: Archived
Updated: 1/1/1970
University of New Mexico
mi
from
Albuquerque, NM
Dose Escalation Study of MLN4924 in Adults With Melanoma
A Phase I, Open-Label, Dose Escalation Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Melanoma
Status: Archived
The Angeles Clinic and Research Institute
mi
from
Santa Monica, CA
Dose Escalation Study of MLN4924 in Adults With Melanoma
A Phase I, Open-Label, Dose Escalation Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Melanoma
Status: Archived
Updated: 1/1/1970
The Angeles Clinic and Research Institute
mi
from
Santa Monica, CA
A Clinical Trial of Dermacorder for Detecting Malignant Skin Lesions
A Phase I Clinical Trial of Dermacorder for Detecting Malignant Skin Lesions
Status: Archived
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
A Clinical Trial of Dermacorder for Detecting Malignant Skin Lesions
A Phase I Clinical Trial of Dermacorder for Detecting Malignant Skin Lesions
Status: Archived
Updated: 1/1/1970
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
A Phase 2, Open Label, Non-Randomized Study to Evaluate the Safety, Tolerability, Immune Response and Clinical Response of Multiple Doses of MKC1106-MT in Subjects With Advanced Melanoma
Status: Archived
UCLA Medical Center
mi
from
Los Angeles, CA
Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
A Phase 2, Open Label, Non-Randomized Study to Evaluate the Safety, Tolerability, Immune Response and Clinical Response of Multiple Doses of MKC1106-MT in Subjects With Advanced Melanoma
Status: Archived
Updated: 1/1/1970
UCLA Medical Center
mi
from
Los Angeles, CA
Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
A Phase 2, Open Label, Non-Randomized Study to Evaluate the Safety, Tolerability, Immune Response and Clinical Response of Multiple Doses of MKC1106-MT in Subjects With Advanced Melanoma
Status: Archived
The Angeles Clinic and Research Institute
mi
from
Santa Monica, CA
Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
A Phase 2, Open Label, Non-Randomized Study to Evaluate the Safety, Tolerability, Immune Response and Clinical Response of Multiple Doses of MKC1106-MT in Subjects With Advanced Melanoma
Status: Archived
Updated: 1/1/1970
The Angeles Clinic and Research Institute
mi
from
Santa Monica, CA
Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
A Phase 2, Open Label, Non-Randomized Study to Evaluate the Safety, Tolerability, Immune Response and Clinical Response of Multiple Doses of MKC1106-MT in Subjects With Advanced Melanoma
Status: Archived
Martin Memorial Health Systems, Stuart - Robert & Carol Weissman Cancer Center
mi
from
Stuart, FL
Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
A Phase 2, Open Label, Non-Randomized Study to Evaluate the Safety, Tolerability, Immune Response and Clinical Response of Multiple Doses of MKC1106-MT in Subjects With Advanced Melanoma
Status: Archived
Updated: 1/1/1970
Martin Memorial Health Systems, Stuart - Robert & Carol Weissman Cancer Center
mi
from
Stuart, FL
Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
A Phase 2, Open Label, Non-Randomized Study to Evaluate the Safety, Tolerability, Immune Response and Clinical Response of Multiple Doses of MKC1106-MT in Subjects With Advanced Melanoma
Status: Archived
Nevada Cancer Institute
mi
from
Las Vegas, NV
Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
A Phase 2, Open Label, Non-Randomized Study to Evaluate the Safety, Tolerability, Immune Response and Clinical Response of Multiple Doses of MKC1106-MT in Subjects With Advanced Melanoma
Status: Archived
Updated: 1/1/1970
Nevada Cancer Institute
mi
from
Las Vegas, NV
Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Phase Ib/II Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Status: Archived
The Angeles Clinic and Research Institute
mi
from
Santa Monica, CA
Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Phase Ib/II Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Status: Archived
Updated: 1/1/1970
The Angeles Clinic and Research Institute
mi
from
Santa Monica, CA
Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Phase Ib/II Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Status: Archived
Unversity of California, San Francisco
mi
from
San Francisco, CA
Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Phase Ib/II Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Status: Archived
Updated: 1/1/1970
Unversity of California, San Francisco
mi
from
San Francisco, CA
Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Phase Ib/II Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Status: Archived
M. D. Anderson Cancer Center
mi
from
Orlando, FL
Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Phase Ib/II Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Status: Archived
Updated: 1/1/1970
M. D. Anderson Cancer Center
mi
from
Orlando, FL
Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Phase Ib/II Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Status: Archived
Emory University
mi
from
Atlanta, GA
Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Phase Ib/II Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Status: Archived
Updated: 1/1/1970
Emory University
mi
from
Atlanta, GA
Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Phase Ib/II Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Status: Archived
Northwestern University
mi
from
Chicago, IL
Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Phase Ib/II Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Status: Archived
Updated: 1/1/1970
Northwestern University
mi
from
Chicago, IL
Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Phase Ib/II Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Status: Archived
Oncology Specialist, SC
mi
from
Park Ridge, IL
Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Phase Ib/II Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Status: Archived
Updated: 1/1/1970
Oncology Specialist, SC
mi
from
Park Ridge, IL
Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Phase Ib/II Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Status: Archived
University of Iowa
mi
from
Iowa City, IA
Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Phase Ib/II Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Status: Archived
Updated: 1/1/1970
University of Iowa
mi
from
Iowa City, IA
Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Phase Ib/II Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Status: Archived
Carolinas Medical Center
mi
from
Charlotte, NC
Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Phase Ib/II Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Status: Archived
Updated: 1/1/1970
Carolinas Medical Center
mi
from
Charlotte, NC
Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Phase Ib/II Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Status: Archived
St Luke'S Hospital And Health Network
mi
from
Bethlehem, PA
Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Phase Ib/II Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Status: Archived
Updated: 1/1/1970
St Luke'S Hospital And Health Network
mi
from
Bethlehem, PA
Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Phase Ib/II Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Status: Archived
University of Washington Medical Center
mi
from
Seattle, WA
Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Phase Ib/II Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Status: Archived
Updated: 1/1/1970
University of Washington Medical Center
mi
from
Seattle, WA
Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy
Lymphokine Activated Killer (LAK) Cell Activity Against Cell Lines In-vitro of LAK Generated in Vivo by Pulse Interleukin-2 Therapy
Status: Archived
Loma Linda Medical Center
mi
from
Loma Linda, CA
Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy
Lymphokine Activated Killer (LAK) Cell Activity Against Cell Lines In-vitro of LAK Generated in Vivo by Pulse Interleukin-2 Therapy
Status: Archived
Updated: 1/1/1970
Loma Linda Medical Center
mi
from
Loma Linda, CA
SciBase International Melanoma Pivotal Study
SciBase International Melanoma Pivotal Study
Status: Archived
University of Arizona
mi
from
Tucson, AZ
SciBase International Melanoma Pivotal Study
SciBase International Melanoma Pivotal Study
Status: Archived
Updated: 1/1/1970
University of Arizona
mi
from
Tucson, AZ
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping
Status: Archived
University of Alabama - Burmingham
mi
from
Birmingham, AL
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping
Status: Archived
Updated: 1/1/1970
University of Alabama - Burmingham
mi
from
Birmingham, AL
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping
Status: Archived
Moores Cancer Center
mi
from
La Jolla, CA
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping
Status: Archived
Updated: 1/1/1970
Moores Cancer Center
mi
from
La Jolla, CA
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping
Status: Archived
California Pacific Medical Center
mi
from
San Francisco, CA
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping
Status: Archived
Updated: 1/1/1970
California Pacific Medical Center
mi
from
San Francisco, CA
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping
Status: Archived
John Wayne Cancer Institute
mi
from
Santa Monica, CA
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping
Status: Archived
Updated: 1/1/1970
John Wayne Cancer Institute
mi
from
Santa Monica, CA
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping
Status: Archived
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping
Status: Archived
Updated: 1/1/1970
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping
Status: Archived
Case Western Reserve Univ
mi
from
Cleveland, OH
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping
Status: Archived
Updated: 1/1/1970
Case Western Reserve Univ
mi
from
Cleveland, OH
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping
Status: Archived
Breast Care Specialists
mi
from
Columbus, OH
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping
Status: Archived
Updated: 1/1/1970
Breast Care Specialists
mi
from
Columbus, OH